Potency and safety analysis of hemp-derived delta-9 products: The hemp vs. cannabis demarcation problem

Add links
Legal status
Legal status
  • N-[2-(4-chlorophenyl)propan-2-yl]-1-pentylindazole-3-carboxamide
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass383.92 g·mol−1
3D model (JSmol)
  • CCCCCN1C2=CC=CC=C2C(=N1)C(=O)NC(C)(C)C3=CC=C(C=C3)Cl
  • InChI=1S/C22H26ClN3O/c1-4-5-8-15-26-19-10-7-6-9-18(19)20(25-26)21(27)24-22(2,3)16-11-13-17(23)14-12-16/h6-7,9-14H,4-5,8,15H2,1-3H3,(H,24,27)

4'Cl-CUMYL-PINACA (also known as SGT-157) is an indazole-3-carboxamide based synthetic cannabinoid compound, first disclosed in a 2014 patent.[1] It has been sold as a designer drug, first reported in 2020 alongside two similar compounds 4'F-CUMYL-5F-PICA (SGT-64) and 4'F-CUMYL-5F-PINACA (SGT-65),[2] and the metabolism of these compounds has been studied to assist with their identification in forensic casework.[3]

4'F-CUMYL-5F-PICA (SGT-64), CAS# 1631074-52-6 [1]
4'F-CUMYL-5F-PINACA (SGT-65), CAS# 1631074-53-7 [2]

See also


  1. ^ WO 2014167530, Bowden MJ, Williamson JP, "Cannabinoid compounds", published 16 October 2014. 
  2. ^ Zangani C, Schifano F, Napoletano F, Arillotta D, Gilgar L, Guirguis A, et al. (2020). "The e-Psychonauts' 'Spiced' World; Assessment of the Synthetic Cannabinoids' Information Available Online". Current Neuropharmacology. 18 (10): 966–1051. doi:10.2174/1570159X18666200302125146. PMC 7709145. PMID 32116194.
  3. ^ Stalberga D, Ingvarsson S, Bessa G, Maas L, Vikingsson S, Persson M, et al. (December 2022). "Metabolism studies of 4'Cl-CUMYL-PINACA, 4'F-CUMYL-5F-PINACA and 4'F-CUMYL-5F-PICA using human hepatocytes and LC-QTOF-MS analysis" (PDF). Basic & Clinical Pharmacology & Toxicology. 132 (3): 263–280. doi:10.1111/bcpt.13829. PMID 36544361. S2CID 255039508.